Brief: Chinook Therapeutics Pauses Dosing Of Chk-336 In Ongoing Phase 1 Trial

Chinook Therapeutics

11/04/2023 13:33

April 11 (Reuters) - Chinook Therapeutics Inc  KDNY.O :
    * CHINOOK THERAPEUTICS ANNOUNCES VOLUNTARY PAUSE IN DOSING
OF
CHK-336 IN ONGOING PHASE 1 CLINICAL TRIAL IN HEALTHY VOLUNTEERS
    * CHINOOK THERAPEUTICS INC - DOSING VOLUNTARILY PAUSED TO
ALLOW A
THOROUGH INVESTIGATION OF A SERIOUS ADVERSE EVENT OCCURRED IN
SINGLE SUBJECT
    * CHINOOK THERAPEUTICS INC - SAE HAD A RAPID ONSET AND RAPID
RECOVERY; FOLLOW-UP OF SUBJECT IS ONGOING
    * CHINOOK THERAPEUTICS INC - UNDERLYING CAUSE OF EVENT IS
BEING
INVESTIGATED AS A POTENTIAL HYPERSENSITIVITY REACTION TO STUDY
DRUG OR ITS EXCIPIENTS

Source text for Eikon:  ID:nGNX5grnDL 
Further company coverage:  KDNY.O 

 ((Reuters.Briefs@thomsonreuters.com;))